Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia

Blood Cancer Journal

Volumn 6, Issue 9, 2016, Pages e473-

  Gokbuget N ^a   Kelsh, M ^b   Chia, V ^b   Advani, A ^c   Bassan, R ^d   Dombret, H ^e   Doubek, M ^f   Fielding, A K ^g   Giebel, S ^h   Haddad, V ⁱ   Hoelzer, D ^a   Holland, C ^j   Ifrah, N ^k   Katz, A ^b   Maniar, T ^b   Martinelli, G ^l   Morgades, M ^m   O'Brien, S ⁿ   Ribera, J M ^m   Rowe, J M ^o   Stein, A ^p   Topp, M ^q   Wadleigh, M ^r   Kantarjian, H ⁿ   more..

^a GOETHE UNIVERSITY   (Germany)

^b AMGEN INC   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d OSPEDALE DELL'ANGELO   (Italy)

^e SAINT LOUIS HOSPITAL   (France)

^f MASARYK UNIVERSITY   (Czech Republic)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h INSTITUTE OF ONCOLOGY   (Poland)

ⁱ AMGEN LTD   (United Kingdom)

^j Amgen Inc   (United States)

^k ANGERS UNIVERSITY HOSPITAL   (France)

^l UNIVERSITY OF BOLOGNA   (Italy)

^m HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

ⁿ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^o RAMBAM MEDICAL CENTER   (Israel)

^p CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^q UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^r DANA FARBER CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85014429789     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2016.84     Document Type: Article

References (31)

1. Katz AJ, Chia VM, Schoonen WM, Kelsh MA. Acute lymphoblastic leukemia: an assessment of international incidence, survival, and disease burden. Cancer Causes Control 2015; 26: 1627–1642. DOI: 10.1007/s10552-015-0657-6
2. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol 2011; 29: 532–543. DOI: 10.1200/JCO.2010.30.1382
3. Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 2007; 109: 944–950. DOI: 10.1182/blood-2006-05-018192
4. Tavernier E, Boiron JM, Huguet F, Bradstock K, Vey N, Kovacsovics T et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia 2007; 21: 1907–1914. DOI: 10.1038/sj.leu.2404824
5. O'Brien S, Thomas D, Ravandi F, Faderl S, Cortes J, Borthakur G et al. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 2008; 113: 3186–3191. DOI: 10.1002/cncr.23919
6. Oriol A, Vives S, Hernandez-Rivas JM, Tormo M, Heras I, Rivas C et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica 2010; 95: 589–596. DOI: 10.3324/haematol.2009.014274
7. Gokbuget N, Stanze D, Beck J, Tormo M, Heras I, Rivas C et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood 2012; 120: 2032–2041. DOI: 10.1182/blood-2011-12-399287
8. Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 2012; 119: 6226–6233. DOI: 10.1182/blood-2012-01-400515
9. Przepiorka D, Ko CW, Deisseroth A, Yancey CL, Candau-Chacon R, Chiu HJ et al. FDA approval: blinatumomab. Clin Cancer Res 2015; 21: 4035–4039. DOI: 10.1158/1078-0432.CCR-15-0612
10. Topp MS, Gokbuget N, Stein AS, Zugmaier G, O’Brien S, Bargou RC et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 2015; 16: 57–66. DOI: 10.1016/S1470-2045(14)71170-2
11. Simon R, Blumenthal GM, Rothenberg ML, Sommer J, Roberts SA, Armstrong DK et al. The role of nonrandomized trials in the evaluation of oncology drugs. Clin Pharmacol Ther 2015; 97: 502–507. DOI: 10.1002/cpt.86
12. ICH E10. 2000 Choice of Control Groups and Related Issues in Clinical Trials. International Conference on Harmonization of Technical Requirements for Regulation of Pharmaceuticals for Human Use. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E10/Step4/E10_Guideline.pdf (accessed 10 September 2015).
13. FDA Blincyto drug approval package. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125557Orig1s000TOC.cfm (accessed 25 February 2016).
14. Blinatumomab EPAR. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR-_Public_assessment_report/human/003731/WC500198227.pdf (accessed 25 February 2016).
15. Gökbuget N, Dombret H, Ribera JM, Fielding AK, Advani A, Bassan R et al. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica 2016, e-pub ahead of print 1 September 2016; pii:haematol.2016.144311.
16. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984; 79: 516–524. DOI: 10.1080/01621459.1984.10478078
17. Greenland S, Rothman K. Modern Epidemiology, 3rd edn. Wolfers Kluen/Lippincott: Philadelphia, 2008.
18. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. Chapman & Hall/CRC: Boca Raton, London, New York, Washington, DC, 1993. DOI: 10.1007/978-1-4899-4541-9
19. Brookmeyer R, Crowley JA. Confidence interval for the median survival time. Biometrics 1982; 38: 29–41. DOI: 10.2307/2530286
20. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. John Wiley & Sons, Inc.: New York, 1980.
21. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41–55. DOI: 10.1093/biomet/70.1.41
22. D’Agostino Jr RB, D’Agostino RB Sr. Estimating treatment effects using observational data. JAMA 2007; 297: 314–316. DOI: 10.1001/jama.297.3.314
23. Rosenbaum PR. Model-based direct adjustment. Am Stat 1987; 82: 387–394. DOI: 10.1080/01621459.1987.10478441
24. Lunceford JK, Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med 2004; 23: 2937–2960. DOI: 10.1002/sim.1903
25. Robins JM, Herna' n MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11: 550–560. DOI: 10.1097/00001648-200009000-00011
26. Hernan MA, Brumback B, Robbins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000; 11: 561–570. DOI: 10.1097/00001648-200009000-00012
27. Koller CA, Kantarjian HM, Thomas D, O’Brien S, Rios MB, Kornblau S et al. The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia. Leukemia 1997; 11: 2039–2044. DOI: 10.1038/sj.leu.2400861
28. Kantarjian HM, Thomas D, Ravandi F, Faderl S, Jabbour E, Garcia-Manero G et al. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer 2010; 116: 5568–5574. DOI: 10.1002/cncr.25354
29. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371: 1507–1517. DOI: 10.1056/NEJMoa1407222
30. Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol 2012; 13: 403–411. DOI: 10.1016/S1470-2045(11)70386-2
31. Topp MS, Stein A, Gökbuget N, Fielding AK, Schuh A, Ribera JM et al. Blinatumomab improved overall survival in patients with relapsed or refractory Philadelphia negative B-cell precursor acute lymphoblastic leukemia in a randomized, open-label phase 3 study (TOWER). Haematologica 2016; 101 (s1): S149.